Multi-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment Risk Assessment
Pleasanton, CA Sep 10, 2025 – GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep-tech Drug Assessment Platform (DAP). This revolutionary system represents the culmination of years of clinical research and development, combining cutting-edge artificial intelligence with a proprietary pathways driven multi-omics engine to transform how therapies are evaluated, optimized, and personalized for patients.
Successful Assessments to Date
The DAP has demonstrated its transformative potential through assessments and enhancements across multiple therapeutic interventions, including:
- p53 agonist-based combination therapy for enhanced lung cancer treatment
- Proprietary combination therapy using protein assembly modulators for ALS
- Optimized treatment protocols for Traumatic Brain Injury study conducted for a major sports league
- Multiple Myeloma therapy optimization
Built on GNQ’s proprietary muti-omics engine containing tens of millions of networked connections based on human biological pathways and insights from the latest research, the platform employs sophisticated AI agents that intelligently apply these insights to therapeutic assessments.
Revolutionary AI-Driven Therapeutic Engine
The DAP delivers unprecedented capabilities in therapeutic evaluation and optimization:
Prescriptive AI
- Predicts and enhances therapy efficacy across diverse patient profiles
- Forecasts toxicity responses with high precision
- Identifies optimal patient populations for specific treatments
Causal AI Optimization
- Utilizes causal inference engine combined with real-world data
- Recommends personalized dosage regimens
- Optimizes therapy by recommending additional compounds to the original formulation
Investment Risk Assessment
- De-risks investments at early stages of drug development
- Differentiates promising candidates from ineffective compounds
- Validates therapeutic potential before costly clinical trials
Executive Leadership Perspectives
Rehan Huda, Chief Executive Officer:
“We are very excited about transformational potential of this platform as we now bring it to the market. The platform is a culmination of many years of hard work and dedication by a very talented team of life sciences, healthcare and technology professionals. I am honored to have been selected as one of the guest speakers on a panel at the RESI Boston Conference to be held on September 17th, 2025. The panel is titled, “AI-Driven Transformation in Life Sciences: Biopharma, Big Pharma, and Investor Perspectives”. This panel will focus on how AI is rapidly reshaping the landscape of drug discovery, development and commercialization. We believe that GNQ Insilico is positioned to be an industry leader in reshaping this landscape.”
Sudhir Saxena, Chief Technology Officer:
“The launch of our Drug Assessment Platform represents a paradigm shift in how we approach precision medicine and drug development. By harnessing the power of our comprehensive systems biology pathways-driven proprietary engine with advanced AI agents, we’re able to predict therapeutic outcomes with unprecedented accuracy. This platform doesn’t just analyze data—it understands the complex interplay of biological pathways, genetic variants, and therapeutic interventions to deliver truly personalized treatment strategies. We’re essentially bringing the power of quantum-level biological understanding to clinical decision-making.”
Dr. Jerome Schentag, Chief Operating Officer:
“Having personally utilized this platform to assess the potential for combining p53 agonists with targeted therapies in lung cancer treatment, I can attest to its transformative impact on therapeutic development. The platform’s ability to identify synergistic combinations and predict patient-specific responses has already shown remarkable promise in our early applications. Because actionable information is available to the clinician in only a few days, the Drug Assessment Platform offers a fundamental advancement in our ability to personalize cancer therapy and optimize treatment outcomes while minimizing adverse effects. The implications for both patient care and pharmaceutical development are profound.”
Market Impact and Applications
The platform addresses critical challenges across the healthcare and pharmaceutical ecosystem:
For Investors:
- Proprietary systems biology models to conduct scientific due diligence on the therapeutic candidate of life sciences companies
- Actionable recommendations for de-risking investment decisions
- Paradigm shift in portfolio optimization of life sciences companies
For Pharmaceutical Companies:
- Early-stage compound evaluation and validation
- Enhancing target therapies to further improve efficacy/safety outcomes
- Optimized clinical trial design and patient selection
For Healthcare Providers:
- Personalized treatment selection and optimization
- Reduced trial-and-error prescribing
- Improved patient outcomes and safety profiles
- Cost-effective therapeutic decisions
Availability and Implementation
The DAP is now available for deployment across healthcare, pharmaceutical companies and investment organizations. The platform offers flexible deployment options, with comprehensive support for integration into existing clinical and research workflows.
About GNQ Insilico Inc.
GNQ Insilico Inc. is a leading TechBio firm that leverages exponential technologies for precision medicine at a personalized level. Founded on the principle that personalized medicine requires a deep understanding of biological complexity, The Company has developed revolutionary platforms that enable truly personalized therapeutic approaches. The Company’s comprehensive digital twin technology and advanced AI-driven assessment capabilities are setting new standards for precision medicine implementation and drug development optimization.
The Company’s multidisciplinary team combines expertise in genomics, systems biology, artificial intelligence, clinical medicine, and pharmaceutical development to deliver solutions that bridge the gap between complex biological data and actionable clinical insights.
Media Contact:
Ghezali Warsi
Business Development
GNQ Insilico Inc.
Email: info@gnq.ai
Company Website: http://www.gnq.ai
Forward-Looking Statements
This press release contains forward-looking statements regarding GNQ’s business prospects, technology capabilities, and market opportunities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.